Search

Ibandronate

[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805] … Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].

Estradiol

Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain. … Estradiol is a naturally occurring hormone circulating endogenously in females.

Oxiconazole

Oxiconazole is an antifungal agent that is commonly found in topical formulations.

Ephedra sinica root

Ephedra is an alkaloid chemical compound traditionally obtained from the plant _Ephedra sinica_. … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for

Gallamine triethiodide

A synthetic nondepolarizing blocking drug. … It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)

Calcium glucoheptonate

They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. … Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium.

Mab-425

Fingolimod

[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.

Esomeprazole

[A177571] Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. … increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.

Hydroxyprogesterone caproate

It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). … In April 2023, the FDA withdrew its approval of Makena and its generics given an unfavorable risk-to-benefit assessment.[L46113]